Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F3 | P13726 | 5/20 | 0.34 |
| ▸ | F2 | P00734 | 5/20 | 0.33 |
| ▸ | CMA1 | P23946 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CTRC | Q99895 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | CLK3 | P49761 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765845 | 0.92 | TDP1 (0.36) | F3F2CMA1TDP1CASP1 | |
| SCHEMBL30765764 | 0.91 | CMA1 (0.40) | CMA1CTRC | |
| SCHEMBL30765579 | 0.88 | F3 (0.39) | F3F2CMA1CASP1CTRC | |
| SCHEMBL30765987 | 0.88 | F2 (0.37) | F3F2CMA1CASP1CTRC | |
| SCHEMBL30765846 | 0.87 | CMA1 (0.38) | CMA1CTRCLMNA | |
| SCHEMBL30765604 | 0.86 | AVPR1B (0.34) | F2CMA1CASP1KDR | |
| SCHEMBL31558416 | 0.85 | KDR (0.33) | F3F2CMA1CTRCCLK2 | |
| SCHEMBL30765643 | 0.82 | NAMPT (0.35) | F3F2LMNA | |
| SCHEMBL30765877 | 0.81 | CMA1 (0.37) | F3F2CMA1CASP1CTRC | |
| SCHEMBL30765795 | 0.81 | POLB (0.40) | F3KDRHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |